ReviewAdvances in experimental medicine and biology2026
Complex Neurobiological Mechanisms and Risk Factors Underlying Late-Life Depression.
Review in Advances in experimental medicine and biology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Late-life depression (LLD) is a prevalent and debilitating disease closely associated with cognitive decline, exacerbation of chronic medical illness, decreased quality of life, and increased societal burden. This review explores the complex neurobiological mechanisms and key risk factors underlying LLD. Inflammation, particularly involving cytokines such as IL-6 and TNF-α and the activation of the NLRP3 inflammasome, plays a central role. Genetic vulnerability, including polymorphisms in serotonin-transporter-linked polymorphic region (5-HTTLPR), BDNF Val66Met, and methylenetetrahydrofolate reductase (MTHFR), interacts with environmental stressors to increase susceptibility. Dysregulation of neurotransmitters such as serotonin, dopamine, norepinephrine, glutamate, and GABA contributes to core depressive symptoms. LLD is also characterized by functional disruptions in large-scale brain networks and structural changes including cortical thinning and hippocampal atrophy. Additionally, HPA (hypothalamic-pituitary-adrenal) axis hyperactivity, gut microbiota dysbiosis, and metabolic disorders such as hypertension and diabetes further exacerbate LLD.LLD is a multifactorial disorder involving complex interactions among neurobiological systems. Effective prevention and management require an integrated, multidisciplinary approach that considers inflammation, genetics, neurotransmission, and brain structure alterations.
Indexed as
Identifiers
42036573What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.